Genomic instability in breast and ovarian cancers: Translation into clinical predictive biomarkers

Cellular and Molecular Life Sciences

Volumn 69, Issue 2, 2012, Pages 223-245

  Vollebergh, Marieke A ^a   Jonkers, Jos ^a   Linn, Sabine C ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

BRCA1; BRCA2; Breast cancer; Double strand break inducing agents; Genomic instability; Ovarian cancer; Predictive markers

Indexed keywords

ANDROGEN RECEPTOR; DOUBLE STRANDED DNA; ESTROGEN RECEPTOR; MESSENGER RNA; OLAPARIB; PLACEBO; PROGESTERONE RECEPTOR; TUMOR MARKER;

BREAST CANCER; CANCER CLASSIFICATION; CHEMOSENSITIVITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME NUMBER; COPY NUMBER VARIATION; DISEASE ASSOCIATION; DNA END JOINING REPAIR; DNA METHYLATION; DNA STRAND BREAKAGE; DRUG RESPONSE; ERCC1 GENE; ERCC5 GENE; EXCISION REPAIR; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENOMIC INSTABILITY; GERM LINE; HISTONE METHYLATION; HUMAN; MISMATCH REPAIR; MLH1 GENE; MUTATIONAL ANALYSIS; MUTATOR GENE; NONHUMAN; OVARY CANCER; PROGNOSIS; PROMOTER REGION; RECOMBINATION REPAIR; REVIEW; TISSUE SPECIFICITY; TUMOR SUPPRESSOR GENE; X CHROMOSOME; XRCC1 GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMANS; MICE; MUTATION; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84856230867     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0809-0     Document Type: Review

References (215)

1. Ferlay J, Shin HR, Bray F et al (2010) GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10 (Internet). International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr
2. Ferlay J, Shin HR, Bray F et al (2010) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. Int J Cancer
3. L Harris H Fritsche R Mennel, et al. 2007 American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J Clin Oncol 25 5287 5312 17954709 1:CAS:528:DC%2BD2sXhsVKnsbzK (Pubitemid 350232263)
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717
5. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 16236738 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
6. H Joensuu PL Kellokumpu-Lehtinen P Bono, et al. 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809 820 16495393 1:CAS:528:DC%2BD28Xhsl2gsrY%3D (Pubitemid 43290919)
7. ER Plummer H Calvert 2007 Targeting poly(ADP-Ribose) polymerase: a two-armed strategy for cancer therapy Clin Cancer Res 13 6252 6256 17975135 1:CAS:528:DC%2BD2sXht1Cgtb7I (Pubitemid 350075012)
8. K Ratnam JA Low 2007 Current development of clinical inhibitors of poly(ADP-Ribose) polymerase in oncology Clin Cancer Res 13 1383 1388 17332279 1:CAS:528:DC%2BD2sXitlSjtr8%3D (Pubitemid 46450426)
9. S Rottenberg AO Nygren M Pajic, et al. 2007 Selective Induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer Proc Natl Acad Sci USA 104 12117 12122 17626183 1:CAS:528:DC%2BD2sXosVWmsro%3D (Pubitemid 47185639)
10. PA Futreal Q Liu D Shattuck-Eidens, et al. 1994 BRCA1 mutations in primary breast and ovarian carcinomas Science 266 120 122 7939630 1:CAS:528:DyaK2cXmslers70%3D (Pubitemid 24345332)
11. Y Miki J Swensen D Shattuck-Eidens, et al. 1994 A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 66 71 7545954 1:CAS:528:DyaK2MXhtF2ns70%3D (Pubitemid 24345325)
12. R Wooster G Bignell J Lancaster, et al. 1995 Identification of the breast cancer susceptibility gene BRCA2 Nature 378 789 792 8524414 1:CAS:528:DyaK28XltFWi (Pubitemid 26004412)
13. MW Audeh J Carmichael RT Penson, et al. 2010 Oral poly(ADP-Ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 245 251 20609468 1:CAS:528:DC%2BC3cXpt1Kktb4%3D
14. A Tutt M Robson JE Garber, et al. 2010 Oral poly(ADP-Ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 235 244 20609467 1:CAS:528:DC%2BC3cXpt1KktLc%3D
15. World Health Organization (2003) Tumours of the breast and female genital organs (WHO/IARC classification of tumours) (IARC WHO Classification of Tumours). IARC Press, Lyon
16. HJ Mackay MF Brady AM Oza, et al. 2010 Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer Int J Gynecol Cancer 20 945 952 20683400
17. G Arpino VJ Bardou GM Clark RM Elledge 2004 Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome Breast Cancer Res 6 R149 R156 15084238
18. EA Rakha ME El Sayed DG Powe, et al. 2008 Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes Eur J Cancer 44 73 83 18035533 (Pubitemid 350256943)
19. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 10963602 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
20. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 11553815 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
21. T Sorlie R Tibshirani J Parker, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423 12829800 1:CAS:528:DC%2BD3sXlsFGntLk%3D (Pubitemid 36842560)
22. C Sotiriou TJ Powles M Dowsett, et al. 2002 Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer Breast Cancer Res 4 R3 12052255
23. R Rouzier CM Perou WF Symmans, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 16115903 1:CAS:528:DC%2BD2MXos1Cjs7k%3D (Pubitemid 41170290)
24. B Kreike M van Kouwenhove H Horlings, et al. 2007 Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas Breast Cancer Res 9 R65 17910759
25. TO Nielsen FD Hsu K Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 15328174 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
26. DR Schwartz SL Kardia KA Shedden, et al. 2002 Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas Cancer Res 62 4722 4729 12183431 1:CAS:528:DC%2BD38XmsVShsb8%3D
27. RW Tothill AV Tinker J George, et al. 2008 Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome Clin Cancer Res 14 5198 5208 18698038 1:CAS:528:DC%2BD1cXpslKgu70%3D
28. T Bonome JY Lee DC Park, et al. 2005 Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary Cancer Res 65 10602 10612 16288054 1:CAS:528:DC%2BD2MXht1Wgu73M (Pubitemid 41743756)
29. G Singer RJ Kurman HW Chang, et al. 2002 Diverse tumorigenic pathways in ovarian serous carcinoma Am J Pathol 160 1223 1228 11943707 1:CAS:528: DC%2BD38XjsFGjsbg%3D (Pubitemid 34411626)
30. G Singer R Oldt III Y Cohen, et al. 2003 Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 484 486 12644542 1:CAS:528:DC%2BD3sXisFCqs70%3D (Pubitemid 36432423)
31. KC Wiegand SP Shah OM Al-Agha, et al. 2010 ARID1A mutations in endometriosis-associated ovarian carcinomas N Engl J Med 363 1532 1543 20942669 1:CAS:528:DC%2BC3cXht12ltrbL
32. J Willner K Wurz KH Allison, et al. 2007 Alternate molecular genetic pathways in ovarian carcinomas of common histological types Hum Pathol 38 607 613 17258789 1:CAS:528:DC%2BD2sXjt1Sht7s%3D (Pubitemid 46399888)
33. KT Kuo TL Mao S Jones, et al. 2009 Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma Am J Pathol 174 1597 1601 19349352 1:CAS:528:DC%2BD1MXlvVWnuro%3D
34. F Buttitta L Felicioni F Barassi, et al. 2006 PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma J Pathol 208 350 355 16353168 1:CAS:528:DC%2BD28XhvFOntbw%3D (Pubitemid 43210521)
35. M Barbareschi F Buttitta L Felicioni, et al. 2007 Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas Clin Cancer Res 13 6064 6069 17947469 1:CAS:528: DC%2BD2sXhtFygs7nL (Pubitemid 350075063)
36. GA Omura MF Brady HD Homesley, et al. 1991 Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the gynecologic oncology group experience J Clin Oncol 9 1138 1150 1904477 1:STN:280: DyaK3M3lvFWlsQ%3D%3D
37. M Cristofanilli A Gonzalez-Angulo N Sneige, et al. 2005 Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes J Clin Oncol 23 41 48 15625359 (Pubitemid 41702621)
38. DR Crotzer CC Sun RL Coleman, et al. 2007 Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary Gynecol Oncol 105 404 408 17292461 (Pubitemid 46590333)
39. KT Kuo TL Mao X Chen, et al. 2010 DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma Clin Cancer Res 16 1997 2008 20233889 1:CAS:528:DC%2BC3cXktFygu7k%3D
40. B Weigelt FC Geyer R Natrajan, et al. 2010 The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type J Pathol 220 45 57 19877120 1:CAS:528:DC%2BC3cXpvFOisg%3D%3D
41. A Bergamaschi YH Kim P Wang, et al. 2006 Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer Genes Chromosomes Cancer 45 1033 1040 16897746 1:CAS:528:DC%2BD28XpvFajsL4%3D (Pubitemid 44435537)
42. L Melchor E Honrado MJ Garcia, et al. 2008 Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes Oncogene 27 3165 3175 18071313 1:CAS:528: DC%2BD1cXlvFSis7k%3D (Pubitemid 351693170)
43. J Prosser AM Thompson G Cranston HJ Evans 1990 Evidence that P53 behaves as a tumour suppressor gene in sporadic breast tumours Oncogene 5 1573 1579 2250913 1:CAS:528:DyaK3MXls1Kksw%3D%3D
44. AL Borresen-Dale 2003 TP53 and breast cancer Hum Mutat 21 292 300 12619115 1:CAS:528:DC%2BD3sXis1yjtLw%3D
45. MF Kohler JR Marks RW Wiseman, et al. 1993 Spectrum of mutation and frequency of allelic deletion of the P53 gene in ovarian cancer J Natl Cancer Inst 85 1513 1519 8360934 1:CAS:528:DyaK2cXhs1ShtbY%3D (Pubitemid 23269187)
46. J Kupryjanczyk AD Thor R Beauchamp, et al. 1993 P53 gene mutations and protein accumulation in human ovarian cancer Proc Natl Acad Sci USA 90 4961 4965 8506342 1:CAS:528:DyaK3sXksVKms7Y%3D (Pubitemid 23182955)
47. WH Wen A Reles IB Runnebaum, et al. 1999 P53 mutations and expression in ovarian cancers: correlation with overall survival Int J Gynecol Pathol 18 29 41 9891239 1:STN:280:DyaK1M7gvVerug%3D%3D (Pubitemid 29028842)
48. G Singer R Stohr L Cope, et al. 2005 Patterns of P53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation Am J Surg Pathol 29 218 224 15644779 (Pubitemid 40170640)
49. E Manie A Vincent-Salomon J Lehmann-Che, et al. 2009 High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors Cancer Res 69 663 671 19147582 1:CAS:528: DC%2BD1MXltFSgtg%3D%3D
50. SA Cannistra 2004 Cancer of the ovary N Engl J Med 351 2519 2529 15590954 1:CAS:528:DC%2BD2cXhtVGksbbM
51. KT Kuo B Guan Y Feng, et al. 2009 Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas Cancer Res 69 4036 4042 19383911 1:CAS:528: DC%2BD1MXltFOktro%3D
52. H Holstege SA Joosse CT van Oostrom, et al. 2009 High Incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer Cancer Res 69 3625 3633 19336573 1:CAS:528:DC%2BD1MXksV2htLw%3D
53. BT Hennessy KM Timms MS Carey, et al. 2010 Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP Ribose) polymerase inhibitors in ovarian cancer J Clin Oncol 28 3570 3576 20606085
54. DF Easton DT Bishop D Ford GP Crockford 1993 Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium Am J Hum Genet 52 678 701 8460634 1:CAS:528: DyaK2cXhtVemurs%3D (Pubitemid 23310135)
55. S Chen G Parmigiani 2007 Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 1329 1333 17416853 (Pubitemid 46706879)
56. S Pruthi BS Gostout NM Lindor 2010 Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer Mayo Clin Proc 85 1111 1120 21123638
57. The Breast Cancer Linkage Consortium 1999 Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium J Natl Cancer Inst 91 1310 1316
58. D Thompson DF Easton 2002 Cancer incidence in BRCA1 mutation carriers J Natl Cancer Inst 94 1358 1365 12237281 1:CAS:528:DC%2BD38Xnt1Gnurs%3D (Pubitemid 35154140)
59. DC van Gent JH Hoeijmakers R Kanaar 2001 Chromosomal stability and the DNA double-stranded break connection Nat Rev Genet 2 196 206 11256071 (Pubitemid 33674018)
60. T Boveri 2008 Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris J Cell Sci 121 Suppl 1 1 84 18089652
61. JH Hoeijmakers 2001 Genome maintenance mechanisms for preventing cancer Nature 411 366 374 11357144 1:CAS:528:DC%2BD3MXktVSjs74%3D (Pubitemid 32467046)
62. AJ Hartlerode R Scully 2009 Mechanisms of double-strand break repair in somatic mammalian cells Biochem J 423 157 168 19772495 1:CAS:528: DC%2BD1MXhtF2lurbN
63. B Pardo B Gomez-Gonzalez A Aguilera 2009 DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship Cell Mol Life Sci 66 1039 1056 19153654 1:CAS:528:DC%2BD1MXjtFKqsb4%3D
64. M Dinkelmann E Spehalski T Stoneham, et al. 2009 Multiple functions of MRN in end-joining pathways during isotype class switching Nat Struct Mol Biol 16 808 813 19633670 1:CAS:528:DC%2BD1MXovFymtbk%3D
65. MS Huen SM Sy J Chen 2010 BRCA1 and its toolbox for the maintenance of genome integrity Nat Rev Mol Cell Biol 11 138 148 20029420 1:CAS:528: DC%2BD1MXhsF2hs7fF
66. RD Kennedy AD D'Andrea 2005 The Fanconi anemia/BRCA pathway: new faces in the crowd Genes Dev 19 2925 2940 16357213 1:CAS:528:DC%2BD28XmtFI%3D (Pubitemid 41798109)
67. JE Cleaver ET Lam I Revet 2009 Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity Nat Rev Genet 10 756 768 19809470 1:CAS:528:DC%2BD1MXht1KrtbrP
68. Bootsma D, Kraemer K, Cleaver J, Hoeijmakers JH (2001) Nucleotide excision repair syndromes: xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. In: Vogelstein B, Kinzler K (eds) The genetic basis of human cancer, 2nd edn. McGraw-Hill, New York, pp 677-703
69. SG Khan KS Oh T Shahlavi, et al. 2006 Reduced XPC DNA repair gene MRNA levels in clinically normal parents of xeroderma pigmentosum patients Carcinogenesis 27 84 94 16081512 1:CAS:528:DC%2BD2MXhtlCmsbbN (Pubitemid 43025247)
70. GT van der Horst H van Steeg RJ Berg, et al. 1997 Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition Cell 89 425 435 9150142 (Pubitemid 27220887)
71. J de Boer H van Steeg RJ Berg, et al. 1999 Mouse model for the DNA repair/basal transcription disorder trichothiodystrophy reveals cancer predisposition Cancer Res 59 3489 3494 10416615 (Pubitemid 29334513)
72. C Lengauer KW Kinzler B Vogelstein 1998 Genetic instabilities in human cancers Nature 396 643 649 9872311 1:CAS:528:DyaK1MXisVWqsQ%3D%3D (Pubitemid 29003936)
73. SS David VL O'Shea S Kundu 2007 Base-excision repair of oxidative DNA damage Nature 447 941 950 17581577 1:CAS:528:DC%2BD2sXms12js74%3D (Pubitemid 46975761)
74. P Taverna HS Hwang JE Schupp, et al. 2003 Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization Cancer Res 63 838 846 12591735 1:CAS:528:DC%2BD3sXht1GqsLw%3D (Pubitemid 36231985)
75. TA De Alencar AC Leitao C Lage 2005 Nitrogen mustard- and half-mustard-induced damage in Escherichia coli requires different DNA repair pathways Mutat Res 582 105 115 15781216 (Pubitemid 40386927)
76. DR McNeill W Lam TL DeWeese, et al. 2009 Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites Mol Cancer Res 7 897 906 19470598 1:CAS:528:DC%2BD1MXns1Skt7s%3D
77. JB Sweasy T Lang D DiMaio 2006 Is base excision repair a tumor suppressor mechanism? Cell Cycle 5 250 259 16418580 1:CAS:528:DC%2BD28XjvFOmt7Y%3D (Pubitemid 43213493)
78. TJ Kinsella 2009 Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers Clin Cancer Res 15 1853 1859 19240165 1:CAS:528:DC%2BD1MXjtF2rsrY%3D
79. F Dantzer G de La Rubia J Menissier-De Murcia, et al. 2000 Base excision repair is impaired in mammalian cells lacking poly(ADP-Ribose) polymerase-1 Biochemistry 39 7559 7569 10858306 1:CAS:528:DC%2BD3cXjs1Knsbo%3D (Pubitemid 30422075)
80. RS Tebbs ML Flannery JJ Meneses, et al. 1999 Requirement for the Xrcc1 DNA base excision repair gene during early mouse development Dev Biol 208 513 529 10191063 1:CAS:528:DyaK1MXitFOnurg%3D (Pubitemid 29184008)
81. N Al Tassan NH Chmiel J Maynard, et al. 2002 Inherited variants of MYH associated with somatic G:C->T:A mutations in colorectal tumors Nat Genet 30 227 232 11818965 1:CAS:528:DC%2BD38XhtFWltb8%3D
82. JR Sampson S Dolwani S Jones, et al. 2003 Autosomal-recessive colorectal adenomatous polyposis due to inherited mutations of MYH Lancet 362 39 41 12853198 1:CAS:528:DC%2BD3sXltF2isrY%3D (Pubitemid 36835819)
83. J Jiricny 2006 The multifaceted mismatch-repair system Nat Rev Mol Cell Biol 7 335 346 16612326 1:CAS:528:DC%2BD28XjslSktrs%3D
84. M Hewish CJ Lord SA Martin, et al. 2010 Mismatch repair deficient colorectal cancer in the era of personalized treatment Nat Rev Clin Oncol 7 197 208 20177404
85. N de Wind M Dekker A Berns, et al. 1995 Inactivation of the Mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer Cell 82 321 330 7628020
86. W Edelmann PE Cohen M Kane, et al. 1996 Meiotic pachytene arrest in MLH1-deficient mice Cell 85 1125 1134 8674118 1:CAS:528:DyaK28XjvF2hsr4%3D (Pubitemid 26231177)
87. R Parsons GM Li MJ Longley, et al. 1993 Hypermutability and mismatch repair deficiency in RER+ tumor cells Cell 75 1227 1236 8261516 1:CAS:528:DyaK2cXhtVemsr4%3D (Pubitemid 24006118)
88. SA Martin A McCarthy LJ Barber, et al. 2009 Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 EMBO Mol Med 1 323 337 20049736 1:CAS:528:DC%2BD1MXhsVSltL%2FL
89. B Evers E Schut BE van der, et al. 2010 A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors Clin Cancer Res 16 99 108 20008842 1:CAS:528:DC%2BC3cXot1Wk
90. SA Martin N McCabe M Mullarkey, et al. 2010 DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1 Cancer Cell 17 235 248 20227038 1:CAS:528:DC%2BC3cXlsVWqtLk%3D
91. C Arnaudeau C Lundin T Helleday 2001 DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells J Mol Biol 307 1235 1245 11292338 1:CAS:528:DC%2BD3MXisVKnt7c%3D (Pubitemid 33027636)
92. JE Jaspers S Rottenberg J Jonkers 2009 Therapeutic options for triple-negative breast cancers with defective homologous recombination Biochim Biophys Acta 1796 266 280 19616605 1:CAS:528:DC%2BD1MXhtFyqsLnE
93. N Turner A Tutt A Ashworth 2004 Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 814 819 15510162 1:CAS:528:DC%2BD2cXos1ymu7g%3D (Pubitemid 39331153)
94. Cancer Genome Atlas Research Network 2011 Integrated genomic analyses of ovarian carcinoma Nature 474 609 615
95. P Chalasani S Kurtin T Dragovich 2008 Response to a third-line mitomycin C(MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation JOP 9 305 308 18469443 (Pubitemid 351864891)
96. MC Villarroel NV Rajeshkumar I Garrido-Laguna, et al. 2011 Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer Mol Cancer Ther 10 3 8 21135251 1:CAS:528:DC%2BC3MXjtFekug%3D%3D
97. VJ Weston CE Oldreive A Skowronska, et al. 2010 The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo Blood 116 4578 4587 20739657 1:CAS:528:DC%2BC3cXhsFGgtbvL
98. Q Chen PC Van der Sluis D Boulware, et al. 2005 The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells Blood 106 698 705 15802532 1:CAS:528:DC%2BD2MXmtleqt7c%3D (Pubitemid 40981268)
99. NG Howlett T Taniguchi S Olson, et al. 2002 Biallelic inactivation of BRCA2 in Fanconi anemia Science 297 606 609 12065746 1:CAS:528: DC%2BD38XlslWrs7k%3D (Pubitemid 34815345)
100. NJ Duker 2002 Chromosome breakage syndromes and cancer Am J Med Genet 115 125 129 12407692 (Pubitemid 35265501)
101. LH Thompson D Schild 2002 Recombinational DNA repair and human disease Mutat Res 509 49 78 12427531 1:CAS:528:DC%2BD38XosFCkt7g%3D (Pubitemid 35341453)
102. JH Olsen JM Hahnemann AL Borresen-Dale, et al. 2001 Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries J Natl Cancer Inst 93 121 127 11208881 1:STN:280:DC%2BD3M7nvF2ltw%3D%3D (Pubitemid 32111989)
103. M Berwick JM Satagopan L Ben Porat, et al. 2007 Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer Cancer Res 67 9591 9596 17909071 1:CAS:528:DC%2BD2sXhtFSnurjE (Pubitemid 47535951)
104. SJ Elledge A Amon 2002 The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients Cancer Cell 1 129 132 12086871 1:CAS:528:DC%2BD38XivVegsbw%3D (Pubitemid 41039159)
105. TF Lane C Deng A Elson, et al. 1995 Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice Genes Dev 9 2712 2722 7590247 1:CAS:528:DyaK2MXpt1Ohtb0%3D
106. ST Marquis JV Rajan A Wynshaw-Boris, et al. 1995 The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues Nat Genet 11 17 26 7550308 1:CAS:528:DyaK2MXnvFels7c%3D
107. S Fan J Wang R Yuan, et al. 1999 BRCA1 inhibition of estrogen receptor signaling in transfected cells Science 284 1354 1356 10334989 1:CAS:528:DyaK1MXjs1Whsb4%3D (Pubitemid 29289660)
108. H Kawai H Li P Chun, et al. 2002 Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells Oncogene 21 7730 7739 12400015 1:CAS:528:DC%2BD38XotFWrtLs%3D (Pubitemid 35398818)
109. CM Eakin MJ Maccoss GL Finney RE Klevit 2007 Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase Proc Natl Acad Sci USA 104 5794 5799 17392432 1:CAS:528:DC%2BD2sXkt1Kgtr8%3D (Pubitemid 47175613)
110. E Dizin I Irminger-Finger 2010 Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1 Int J Biochem Cell Biol 42 693 700 20060929 1:CAS:528:DC%2BC3cXivFGru7k%3D
111. SR Lakhani MJ Van De Vijver J Jacquemier, et al. 2002 The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and P53 in Patients with mutations in BRCA1 and BRCA2 J Clin Oncol 20 2310 2318 11981002 1:CAS:528: DC%2BD38XktVKrs7o%3D (Pubitemid 34441658)
112. J Palacios E Honrado A Osorio, et al. 2005 Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers Breast Cancer Res Treat 90 5 14 15770521 1:CAS:528:DC%2BD2MXit1Olur4%3D (Pubitemid 40486996)
113. E Lim F Vaillant D Wu, et al. 2009 Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers Nat Med 15 907 913 19648928 1:CAS:528:DC%2BD1MXpt1Onsro%3D
114. G Molyneux FC Geyer FA Magnay, et al. 2010 BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells Cell Stem Cell 7 403 417 20804975 1:CAS:528:DC%2BC3cXhtVyrurbK
115. W Jin Y Chen GH Di, et al. 2008 Estrogen receptor (ER) beta or P53 attenuates ERalpha-mediated transcriptional activation on the BRCA2 promoter J Biol Chem 283 29671 29680 18765668 1:CAS:528:DC%2BD1cXht1ynt7vM
116. Y Ma P Katiyar LP Jones, et al. 2006 The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells Mol Endocrinol 20 14 34 16109739 1:CAS:528:DC%2BD28XjslemtA%3D%3D (Pubitemid 43011667)
117. AJ Poole Y Li Y Kim, et al. 2006 Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist Science 314 1467 1470 17138902 1:CAS:528:DC%2BD28Xht1CntrnN (Pubitemid 44871955)
118. TA King ML Gemignani W Li, et al. 2004 Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers Cancer Res 64 5051 5053 15289302 1:CAS:528:DC%2BD2cXmtF2mtrY%3D (Pubitemid 39006516)
119. PA Mote JA Leary KA Avery, et al. 2004 Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A Genes Chromosomes Cancer 39 236 248 14732925 1:CAS:528:DC%2BD2cXhvF2qs7Y%3D (Pubitemid 38209584)
120. J Boney-Montoya YS Ziegler CD Curtis, et al. 2010 Long-range transcriptional control of progesterone receptor gene expression Mol Endocrinol 24 346 358 19952285 1:CAS:528:DC%2BC3cXhslejsr4%3D
121. R Bachelier X Xu C Li, et al. 2005 Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice Oncol Rep 14 1117 1120 16211273
122. TR Rebbeck ND Kauff SM Domchek 2009 Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 80 87 19141781 1:CAS:528: DC%2BD1MXhtVehsbo%3D
123. JJ Park RA Irvine G Buchanan, et al. 2000 Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor Cancer Res 60 5946 5949 11085509 1:CAS:528:DC%2BD3cXotV2lsrs%3D
124. S Yeh YC Hu M Rahman, et al. 2000 Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells Proc Natl Acad Sci USA 97 11256 11261 11016951 1:CAS:528:DC%2BD3cXnsF2rtbs%3D
125. S Shin IM Verma 2003 BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription Proc Natl Acad Sci USA 100 7201 7206 12756300 1:CAS:528:DC%2BD3sXkslOmsrw%3D (Pubitemid 36706416)
126. EM Berns MJ Dirkzwager-Kiel V Kuenen-Boumeester, et al. 2003 Androgen pathway dysregulation in BRCA1-mutated breast tumors Breast Cancer Res Treat 79 121 127 12779088 1:CAS:528:DC%2BD3sXivFOitLY%3D (Pubitemid 36561049)
127. AJ Swerdlow MJ Schoemaker CD Higgins, et al. 2005 Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study J Natl Cancer Inst 97 1204 1210 16106025 (Pubitemid 41258226)
128. LA Brinton JD Carreon GL Gierach, et al. 2010 Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database Breast Cancer Res Treat 119 185 192 19330525
129. MJ Schoemaker AJ Swerdlow CD Higgins, et al. 2008 Cancer incidence in women with turner syndrome in Great Britain: a national cohort study Lancet Oncol 9 239 246 18282803
130. P Bosze A Toth M Torok 2006 Hormone replacement and the risk of breast cancer in Turner's syndrome N Engl J Med 355 2599 2600 17167149 (Pubitemid 44917530)
131. GJ Pageau LL Hall S Ganesan, et al. 2007 The disappearing Barr body in breast and ovarian cancers Nat Rev Cancer 7 628 633 17611545 1:CAS:528:DC%2BD2sXotVKqsr4%3D (Pubitemid 47106629)
132. S Ganesan DP Silver RA Greenberg, et al. 2002 BRCA1 supports XIST RNA concentration on the inactive X chromosome Cell 111 393 405 12419249 1:CAS:528:DC%2BD38XovVaku7o%3D (Pubitemid 35341392)
133. AL Richardson ZC Wang A De Nicolo, et al. 2006 X chromosomal abnormalities in basal-like human breast cancer Cancer Cell 9 121 132 16473279 1:CAS:528:DC%2BD28XhvFynsrg%3D (Pubitemid 43202662)
134. GJ Pageau JB Lawrence 2006 BRCA1 foci in normal s-phase nuclei are linked to interphase centromeres and replication of pericentric heterochromatin J Cell Biol 175 693 701 17145961 1:CAS:528:DC%2BD28XhtlWgt7jM (Pubitemid 44878501)
135. GJ Pageau LL Hall JB Lawrence 2007 BRCA1 does not paint the inactive X to Localize XIST RNA but may contribute to broad changes in cancer that impact XIST and Xi heterochromatin J Cell Biochem 100 835 850 17146760 1:CAS:528:DC%2BD2sXhvFGmurs%3D
136. D Thompson D Easton 2002 Variation in BRCA1 cancer risks by mutation position Cancer Epidemiol Biomarkers Prev 11 329 336 11927492 1:CAS:528:DC%2BD38XjtlCmtrw%3D (Pubitemid 34408211)
137. PC Fong DS Boss TA Yap, et al. 2009 Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 123 134 19553641 1:CAS:528:DC%2BD1MXosVKrtrw%3D
138. Ledermann JA, Harter P, Gourley C et al (2011) Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with
139. DF Hayes RC Bast CE Desch, et al. 1996 Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers J Natl Cancer Inst 88 1456 1466 8841020 1:STN:280:DyaK28vjvVKlsg%3D%3D (Pubitemid 26340047)
140. HM Kuerer LA Newman TL Smith, et al. 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 10080586 1:CAS:528:DyaK1MXht1Wmur4%3D (Pubitemid 29075229)
141. DJ Sargent BA Conley C Allegra L Collette 2005 Clinical trial designs for predictive marker validation in cancer treatment trials J Clin Oncol 23 2020 2027 15774793 (Pubitemid 46211382)
142. Y Ben David A Chetrit G Hirsh-Yechezkel, et al. 2002 Effect of BRCA mutations on the length of survival in epithelial ovarian tumors J Clin Oncol 20 463 466 11786575 1:CAS:528:DC%2BD38XovVKiug%3D%3D (Pubitemid 34072530)
143. A Chetrit G Hirsh-Yechezkel Y Ben David, et al. 2008 Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer J Clin Oncol 26 20 25 18165636
144. HA Risch JR McLaughlin DE Cole, et al. 2006 Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada J Natl Cancer Inst 98 1694 1706 17148771 1:CAS:528:DC%2BD28XhtlCru7nJ (Pubitemid 44942707)
145. T Byrski J Gronwald T Huzarski, et al. 2010 Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy J Clin Oncol 28 375 379 20008645 1:CAS:528:DC%2BC3cXivFart74%3D
146. DP Silver AL Richardson AC Eklund, et al. 2010 Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 28 1145 1153 20100965 1:CAS:528:DC%2BC3cXktF2ltLk%3D
147. A Perez-Valles M Martorell-Cebollada E Nogueira-Vazquez, et al. 2001 The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study J Clin Pathol 54 476 480 11376024 1:STN:280:DC%2BD3M3ps1Oltw%3D%3D (Pubitemid 32531100)
148. JW Chiang BY Karlan L Cass RL Baldwin 2006 BRCA1 promoter methylation predicts adverse ovarian cancer prognosis Gynecol Oncol 101 403 410 16360812 1:CAS:528:DC%2BD28XkvVClsbY%3D (Pubitemid 43729975)
149. JM Teodoridis J Hall S Marsh, et al. 2005 CpG island methylation of DNA damage response genes in advanced ovarian cancer Cancer Res 65 8961 8967 16204069 1:CAS:528:DC%2BD2MXhtVKiu7rN (Pubitemid 41377387)
150. P Chaudhry R Srinivasan FD Patel 2009 Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC) Cancer Invest 27 877 884 19548140 1:CAS:528:DC%2BD1MXhtVygtL7E
151. RE Buller MS Shahin JP Geisler, et al. 2002 Failure of BRCA1 dysfunction to alter ovarian cancer survival Clin Cancer Res 8 1196 1202 12006538 1:CAS:528:DC%2BD38XksVWjsr0%3D (Pubitemid 34520421)
152. E Dejeux JA Ronneberg H Solvang, et al. 2010 DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response Mol Cancer 9 68 20338046
153. J Lehmann-Che F Andre C Desmedt, et al. 2010 Cyclophosphamide dose intensification may circumvent anthracycline resistance of P53 mutant breast cancers Oncologist 15 246 252 20228131 1:CAS:528:DC%2BC3cXlsFClt74%3D
154. C Egawa K Motomura Y Miyoshi, et al. 2003 Increased expression of BRCA1 MRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers Breast Cancer Res Treat 78 45 50 12611456 1:CAS:528: DC%2BD3sXntV2rtw%3D%3D (Pubitemid 36223016)
155. M Margeli B Cirauqui E Castella, et al. 2010 The prognostic value of BRCA1 MRNA expression levels following neoadjuvant chemotherapy in breast cancer PLoS ONE 5 e9499 20209131
156. JE Quinn CR James GE Stewart, et al. 2007 BRCA1 MRNA expression levels predict for overall survival in ovarian cancer after chemotherapy Clin Cancer Res 13 7413 7420 18094425 1:CAS:528:DC%2BD2sXhsVCktr3J
157. J Weberpals K Garbuio A O'Brien, et al. 2009 The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer Int J Cancer 124 806 815 19035454 1:CAS:528:DC%2BD1MXhvVShsro%3D
158. LJ 't Veer H Dai MJ Van De Vijver, et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 530 536 11823860 (Pubitemid 34130608)
159. AA Rodriguez A Makris MF Wu, et al. 2010 DNA repair signature is associated with anthracycline response in triple negative breast cancer patients Breast Cancer Res Treat 123 189 196 20582464 1:CAS:528:DC%2BC3cXosleksbk%3D
160. Konstantinopoulos PA, Spentzos D, Karlan BY et al (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol
161. Lips EH, Mulder L, Hannemann J et al (2010) Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol
162. Vollebergh MA, Lips EH, Nederlof PM et al (2010) An ACGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol
163. J Crown 2004 Smart bombs versus blunderbusses: high-dose chemotherapy for breast cancer Lancet 364 1299 1300 15474123 (Pubitemid 39335812)
164. F Huang YB Kushner A Langleben WD Foulkes 2009 Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer Nat Rev Clin Oncol 6 488 492 19644536 1:CAS:528:DC%2BD1MXpsFyhsbc%3D
165. Joosse SA, Brandwijk KI, Devilee P et al (2010) Prediction of BRCA2-association in hereditary breast carcinomas using Array-CGH. Breast Cancer Res Treat
166. S Alvarez R Diaz-Uriarte A Osorio, et al. 2005 A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation Clin Cancer Res 11 1146 1153 15709182 1:CAS:528:DC%2BD2MXht1ynt7g%3D (Pubitemid 40175764)
167. RI Yarden LC Brody 1999 BRCA1 interacts with components of the histone deacetylase complex Proc Natl Acad Sci USA 96 4983 4988 10220405 1:CAS:528:DyaK1MXjtVKmsbs%3D (Pubitemid 29214522)
168. DA Bochar L Wang H Beniya, et al. 2000 BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer Cell 102 257 265 10943845 1:CAS:528:DC%2BD3cXltl2hs78%3D
169. KP Suijkerbuijk MJ Fackler S Sukumar, et al. 2008 Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer Ann Oncol 19 1870 1874 18647968 1:STN:280:DC%2BD1cnosVKmsg%3D%3D
170. JM Flanagan S Cocciardi N Waddell, et al. 2010 DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status Am J Hum Genet 86 420 433 20206335 1:CAS:528:DC%2BC3cXlt1Kntb4%3D
171. K Holm C Hegardt J Staaf, et al. 2010 Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns Breast Cancer Res 12 R36 20565864
172. A Wiley D Katsaros H Chen, et al. 2006 Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential Cancer 107 299 308 16773633 1:CAS:528:DC%2BD28Xnsl2mtLo%3D (Pubitemid 44036559)
173. SV Sharma DY Lee B Li, et al. 2010 A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 69 80 20371346 1:CAS:528:DC%2BC3cXlsVSgtb8%3D
174. K Soderlund L Skoog T Fornander MS Askmalm 2007 The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer Radiother Oncol 84 242 251 17707537 (Pubitemid 47371156)
175. K Soderlund O Stal L Skoog, et al. 2007 Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer Int J Radiat Oncol Biol Phys 68 50 58 17337132 (Pubitemid 46589837)
176. T Taniguchi M Tischkowitz N Ameziane, et al. 2003 Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat Med 9 568 574 12692539 1:CAS:528:DC%2BD3sXjtlamtLo%3D (Pubitemid 36597103)
177. Z Wang M Li S Lu, et al. 2006 Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway Cancer Biol Ther 5 256 260 16418574 1:CAS:528: DC%2BD28XntlWkuro%3D
178. SL Lim P Smith N Syed, et al. 2008 Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer Br J Cancer 98 1452 1456 18414472 1:CAS:528:DC%2BD1cXks12gu7g%3D (Pubitemid 351543586)
179. M Dabholkar J Vionnet F Bostick-Bruton, et al. 1994 Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy J Clin Invest 94 703 708 8040325 1:CAS:528:DyaK2cXlsVymsrg%3D (Pubitemid 24251002)
180. M Dabholkar K Thornton J Vionnet, et al. 2000 Increased MRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased MRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues Biochem Pharmacol 60 1611 1619 11077043 1:CAS:528:DC%2BD3cXotVCrt7s%3D
181. S Kang W Ju JW Kim, et al. 2006 Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer Exp Mol Med 38 320 324 16819291 1:CAS:528:DC%2BD28XmvFyitLs%3D (Pubitemid 44033245)
182. KD Steffensen M Waldstrom U Jeppesen, et al. 2008 Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer Int J Gynecol Cancer 18 702 710 17961161 1:STN:280:DC%2BD1crisl2ltQ%3D%3D (Pubitemid 352020157)
183. KD Steffensen M Waldstrom A Jakobsen 2009 The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer Int J Gynecol Cancer 19 820 825 19574766
184. CS Walsh S Ogawa H Karahashi, et al. 2008 ERCC5 is a novel biomarker of ovarian cancer prognosis J Clin Oncol 26 2952 2958 18565881 1:CAS:528: DC%2BD1cXoslOqs7k%3D
185. KA Olaussen A Dunant P Fouret, et al. 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 983 991 16957145 1:CAS:528:DC%2BD28XpsFKmtLw%3D (Pubitemid 44343542)
186. A Al Attar L Gossage KR Fareed, et al. 2010 Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers Br J Cancer 102 704 709 20087352 1:CAS:528:DC%2BC3cXitVWgt70%3D
187. M Jaremko C Justenhoven W Schroth, et al. 2007 Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer Pharmacogenet Genomics 17 529 538 17558308 1:CAS:528:DC%2BD2sXmtlShsL4%3D (Pubitemid 46905219)
188. MA Bewick MS Conlon RM Lafrenie 2006 Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer J Clin Oncol 24 5645 5651 17116943 1:CAS:528:DC%2BD2sXhtVChsrk%3D (Pubitemid 46631304)
189. S Aebi B Kurdi-Haidar R Gordon, et al. 1996 Loss of DNA mismatch repair in acquired resistance to cisplatin Cancer Res 56 3087 3090 8674066 1:CAS:528:DyaK28XjvFCkt7c%3D (Pubitemid 26199755)
190. HJ Mackay D Cameron M Rahilly, et al. 2000 Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival J Clin Oncol 18 87 93 10623697 (Pubitemid 30036340)
191. G Samimi D Fink NM Varki, et al. 2000 Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy Clin Cancer Res 6 1415 1421 10778972 1:CAS:528:DC%2BD3cXjtVOqtL8%3D (Pubitemid 30226229)
192. M Scartozzi M De Nictolis E Galizia, et al. 2003 Loss of HMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients Eur J Cancer 39 1144 1149 12736115 1:CAS:528:DC%2BD3sXjsVaru7s%3D (Pubitemid 36555873)
193. G Gifford J Paul PA Vasey, et al. 2004 The acquisition of HMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin Cancer Res 10 4420 4426 15240532 1:CAS:528: DC%2BD2cXlsVWlt7c%3D (Pubitemid 38878884)
194. PJ Wild A Reichle R Andreesen, et al. 2004 Microsatellite instability predicts poor short-term survival in patients with advanced breast cancer after high-dose chemotherapy and autologous stem-cell transplantation Clin Cancer Res 10 556 564 14760077 1:CAS:528:DC%2BD2cXovVGqsg%3D%3D (Pubitemid 38173994)
195. J Helleman IL van Staveren WN Dinjens, et al. 2006 Mismatch repair and treatment resistance in ovarian cancer BMC Cancer 6 201 16879751
196. BP Chintamani Jha V Bhandari, et al. 2007 The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer Int Semin Surg Oncol 4 5
197. V Materna P Surowiak E Markwitz, et al. 2007 Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients Oncol Rep 17 505 516 17273726 1:CAS:528:DC%2BD2sXivF2hurc%3D
198. SA Joosse EH van Beers IH Tielen, et al. 2009 Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with Array-CGH Breast Cancer Res Treat 116 479 489 18704682 1:CAS:528:DC%2BD1MXhtFGmtrzF
199. OA Stefansson JG Jonasson OT Johannsson, et al. 2009 Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes Breast Cancer Res 11 R47 19589159
200. H Holstege BE van A Velds, et al. 2010 Cross-species comparison of ACGH data from mouse and human B BMC Cancer 10 455 20735817 1:CAS:528: DC%2BC3cXhtVynsr%2FF
201. Smid M, Hoes M, Sieuwerts AM et al (2010) Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat
202. Juul N, Wang Y, Kim J et al (2009) A genomic-profile derived summary measure of chromosomal breakpoints predicts response to treatment with the DNA-damaging agent cisplatin. Cancer Res 69:Abstract nr 111
203. K Leunen O Gevaert A Daemen, et al. 2009 Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways Hum Mutat 30 1693 1702 19802895 1:CAS:528:DC%2BC3cXkvFOmtA%3D%3D
204. M Meyerson S Gabriel G Getz 2010 Advances in understanding cancer genomes through second-generation sequencing Nat Rev Genet 11 685 696 20847746 1:CAS:528:DC%2BC3cXhtFyju7%2FJ
205. PJ Stephens DJ McBride ML Lin, et al. 2009 Complex landscapes of somatic rearrangement in human breast cancer genomes Nature 462 1005 1010 20033038 1:CAS:528:DC%2BD1MXhs1SktbrN
206. I Varela C Klijn PJ Stephens, et al. 2010 Somatic structural rearrangements in genetically engineered mouse mammary tumors Genome Biol 11 R100 20942901 1:CAS:528:DC%2BC3cXhsVahs7nE
207. H Willers AG Taghian CM Luo, et al. 2009 Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies Mol Cancer Res 7 1304 1309 19671671 1:CAS:528:DC%2BD1MXhtVWrsL%2FK
208. H Asakawa H Koizumi A Koike, et al. 2010 Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins Breast Cancer Res 12 R17 20205718
209. A Mukhopadhyay A Elattar A Cerbinskaite, et al. 2010 Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-Ribose) polymerase inhibitors Clin Cancer Res 16 2344 2351 20371688 1:CAS:528: DC%2BC3cXkslSmu7c%3D
210. MK Graeser A McCarthy CJ Lord, et al. 2010 A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer Clin Cancer Res 16 6159 6168 20802015 1:CAS:528:DC%2BC3cXhsFOjtr%2FI
211. SL Edwards R Brough CJ Lord, et al. 2008 Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 1111 1115 18264088 1:CAS:528: DC%2BD1cXisFWjtrw%3D (Pubitemid 351317441)
212. EM Swisher W Sakai BY Karlan, et al. 2008 Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance Cancer Res 68 2581 2586 18413725 1:CAS:528:DC%2BD1cXks1Git7c%3D (Pubitemid 351556255)
213. P Bouwman A Aly JM Escandell, et al. 2010 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers Nat Struct Mol Biol 17 688 695 20453858 1:CAS:528:DC%2BC3cXlslyqtLo%3D
214. AM Mendes-Pereira SA Martin R Brough, et al. 2009 Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Mol Med 1 315 322 20049735 1:CAS:528:DC%2BD1MXhsVSltL%2FK
215. S Rottenberg JE Jaspers A Kersbergen, et al. 2008 High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc Natl Acad Sci USA 105 17079 17084 18971340 1:CAS:528:DC%2BD1cXhtlKlsr7F